세계의 혈액 분석기 및 시약 시장 : 시장 규모, 점유율, 동향 - 제품 및 서비스별, 가격별, 용도별, 최종 사용자별 - 예측(-2029년)

The global hematology analyzers and reagents market is projected to reach USD 8.8 billion by 2029 from USD 6.6 billion in 2024, growing at a CAGR of 6.1% during the forecast period. The technological advancements of hematology analyzers and reagents methods are one of the major factors anticipated to boost market growth in the forecasting years. Additionally, the high cost of hematology analyzers and reagents, the lack of skilled professionals in emerging countries, along the slow adoption of advanced hematology instruments in emerging economies affect the growth of the hematology analyzers and reagents market.

"The hematology products and services segment to hold the largest share of the market in 2024."

Based on product and services, hematology analyzers and reagents are segmented into hematology products and services, hemostasis products and services and immunohematology products and services. The hematology products & services segment is expected to dominate the hematology analyzers and reagents market during the forecast period. Further the hematology products & services segment is divided into three sub-segments: instruments, reagents and consumables and services. With the increasing adoption of POC testing hematology analyzers in emerging economies and the launch of technologically advanced hematology products worldwide leads to the growth of this market segment.

"The low-range hematology analyzers segment to hold the largest share of the market in 2024."

Based on price range, the hematology analyzers and reagents market is segmented into high-range hematology analyzers, mid-range hematology analyzers and low-range hematology analyzers. The hematology analyzers and reagents market is expected to be dominated by the low-range hematology analyzers segment during the forecast period. The low-range hematology analyzers are expected to grow due to their affordable costing compared to high-range hematology analyzers and mid-range hematology analyzers

"The standalone analyzers segment to hold the largest share of the market in 2024."

Based on the usage type, the hematology analyzers and reagents market is segmented into standalone analyzers and point-of-care analyzers segments. The standalone analyzers segment is projected to dominate the hematology analyzers and reagents market throughout the forecast period. Growing adoption of these systems in acute care settings for hospitals and reference laboratories. leads to the increasing growth of the segment in the market.

"The commercial service providers segment to hold the largest share of the market in 2024."

The end user market is segmented into commercial service providers, hospital laboratories, government reference laboratories, and research & academic institutes. Commercial service providers accounted for the largest share of the global hematology analyzers and reagents market in 2023 during the forecasted years. This can be attributed to the attributed to the growing outsourcing of R&D activities to commercial service providers especially in emerging economies.

"The market in the APAC region is expected to register highest growth rate for hematology analyzers and reagents in 2024."

The hematology analyzers and reagents market covers five key geographies-North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, a significant market share for hematology analyzers and reagents was held by the market in the North American region, comprising the US and Canada. On the other hand, the Asia Pacific market is estimated to register the highest growth rate during the forecast period. The increasing market penetration opportunities in emerging APAC countries led to the growth of the hematology analyzers and reagents market in this region.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1- 25%, Tier 2- 30%, and Tier 3- 45%
• By Designation: D-level- 30%, C- Level- 23%, and Others- 47%
• By Region: North America- 40%, Europe- 30%, Asia Pacific- 22%, Latin America- 6%, MEA- 2%

The prominent players in the hematology analyzers and reagents market are F. Hoffmann-La Roche Ltd (Switzerland), Abbott Laboratories (US), Danaher Corporation (US), Diatron (Hungary), Drew Scientific (US), Siemens Healthineers (Germany), Sysmex Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Horiba Ltd. (Japan), Nihon Kohden Corporation (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), BioSystems (Spain), and QuidelOrtho Corporation (US), among others.

Research Coverage

This report studies the hematology analyzers and reagents market based on product and services, price range, application, modality, end user, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.

This report provides insights on the following pointers:

• Analysis of key drivers (Increasing need for technological advancements, Integration of hematology analyzers with flow cytometry, Increasing number of blood donations), restraints (High costs associated with advanced hematology analyzers), opportunities (Increased awareness among end users about advanced hematology analyzers, Increasing market penetration opportunities in emerging countries, Emergence of microfluidics), and challenges (Stringent and time-consuming regulatory process) influencing the growth of the hematology analyzers and reagents market
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the hematology analyzers and reagents market
• Service Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service developments in the hematology analyzers and reagents market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new services, growing geographies, and recent developments in the hematology analyzers and reagents market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and services of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 MARKET STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 List of secondary sources
  • 2.1.2 PRIMARY DATA
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
  • 2.2.2 PRODUCT-BASED MARKET ESTIMATION
  • 2.2.3 PRIMARY RESEARCH VALIDATION
• 2.3 DATA TRIANGULATION AND MARKET BREAKDOWN
• 2.4 RESEARCH ASSUMPTIONS
  • 2.4.1 STUDY ASSUMPTIONS
• 2.5 RESEARCH LIMITATIONS
• 2.6 RISK ASSESSMENT
  • 2.6.1 RISK ASSESSMENT ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HEMATOLOGY ANALYZERS AND REAGENTS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT AND COUNTRY (2023)
• 4.3 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 HEMATOLOGY ANALYZERS AND REAGENTS MARKET: REGIONAL MIX, 2022-2029 (USD MILLION)

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing incidence of blood disorders
    • 5.2.1.2 Growing number of blood donations
    • 5.2.1.3 Rising technological advancements
    • 5.2.1.4 Integration of hematology analyzers with flow cytometry
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High cost of advanced hematology analyzers
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Increasing uptake of automated hematology analyzers
    • 5.2.3.2 Growth potential of emerging economies
    • 5.2.3.3 Emergence of microfluidics
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory guidelines
    • 5.2.4.2 Shortage of skilled professionals in emerging markets
• 5.3 REGULATORY SCENARIO
  • 5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
  • 5.3.2 REGULATORY TRENDS
    • 5.3.2.1 North America
      • 5.3.2.1.1 US
    • 5.3.2.2 Europe
    • 5.3.2.3 Asia Pacific
      • 5.3.2.3.1 India
      • 5.3.2.3.2 China
• 5.4 REIMBURSEMENT SCENARIO
• 5.5 VALUE CHAIN ANALYSIS
  • 5.5.1 RESEARCH & DEVELOPMENT
  • 5.5.2 PROCUREMENT & PRODUCT DEVELOPMENT
  • 5.5.3 MARKETING, SALES, AND DISTRIBUTION
• 5.6 SUPPLY CHAIN ANALYSIS
  • 5.6.1 PROMINENT COMPANIES
  • 5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES
  • 5.6.3 END USERS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 DEGREE OF COMPETITION
  • 5.8.2 BARGAINING POWER OF BUYERS
  • 5.8.3 BARGAINING POWER OF SUPPLIERS
  • 5.8.4 THREAT OF NEW ENTRANTS
  • 5.8.5 THREAT OF SUBSTITUTES
• 5.9 TRADE DATA ANALYSIS
• 5.10 PATENT ANALYSIS
• 5.11 PRICING ANALYSIS
• 5.12 TECHNOLOGY ANALYSIS
  • 5.12.1 KEY TECHNOLOGIES
    • 5.12.1.1 Flow cytometry
    • 5.12.1.2 Digital microscopy and image analysis
    • 5.12.1.3 Polymerase chain reaction (PCR) and next-generation sequencing (NGS)
    • 5.12.1.4 Microfluidics
  • 5.12.2 ADJACENT TECHNOLOGIES
    • 5.12.2.1 Bioinformatics
    • 5.12.2.2 Wearable health technology
    • 5.12.2.3 Point-of-care testing (POCT) devices
  • 5.12.3 COMPLEMENTARY TECHNOLOGIES
    • 5.12.3.1 Immunohistochemistry (IHC)
    • 5.12.3.2 Spectrophotometry
    • 5.12.3.3 Serological testing
• 5.13 KEY CONFERENCES AND EVENTS, 2024
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 KEY BUYING CRITERIA
• 5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.16 INVESTMENT & FUNDING SCENARIO
• 5.17 UNMET NEEDS
• 5.18 USE OF GENERATIVE AI IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET

6 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 HEMATOLOGY PRODUCTS & SERVICES
  • 6.2.1 REAGENTS & CONSUMABLES
    • 6.2.1.1 Hematology reagents
      • 6.2.1.1.1 Growing preference for reagent rental business models to drive market
    • 6.2.1.2 Hematology consumables
      • 6.2.1.2.1 Recurring requirement to boost demand
    • 6.2.1.3 Controls & calibrators
      • 6.2.1.3.1 Ability to monitor multiple parameters to fuel uptake
    • 6.2.1.4 Slide stainers & makers
      • 6.2.1.4.1 Ability to provide reliable & uniform staining results to fuel uptake
  • 6.2.2 INSTRUMENTS
    • 6.2.2.1 5-part and 6-part fully automated hematology analyzers
      • 6.2.2.1.1 Identification and classification of WBCs to drive market
    • 6.2.2.2 3-part fully automated hematology analyzers
      • 6.2.2.2.1 Low maintenance costs to fuel uptake
    • 6.2.2.3 Point-of-care testing hematology analyzers
      • 6.2.2.3.1 Increasing preference towards home testing of blood levels to support market growth
    • 6.2.2.4 Semi-automated hematology analyzers
      • 6.2.2.4.1 Need for manual interruption to restrain market adoption
  • 6.2.3 SERVICES
    • 6.2.3.1 High adoption of diagnostic techniques to boost demand
• 6.3 HEMOSTASIS PRODUCTS & SERVICES
  • 6.3.1 HEMOSTASIS REAGENTS & CONSUMABLES
    • 6.3.1.1 Rising prevalence of coagulation disorders to support growth
  • 6.3.2 HEMOSTASIS INSTRUMENTS
    • 6.3.2.1 High productivity with low complexities to drive market
  • 6.3.3 HEMOSTASIS SERVICES
    • 6.3.3.1 Advancements in hemostasis diagnostic techniques to support market growth
• 6.4 IMMUNOHEMATOLOGY PRODUCTS & SERVICES
  • 6.4.1 IMMUNOHEMATOLOGY REAGENTS & CONSUMABLES
    • 6.4.1.1 Development of novel immunohematology reagents to drive market
  • 6.4.2 IMMUNOHEMATOLOGY INSTRUMENTS
    • 6.4.2.1 Growing automation in immunohematology labs to boost demand
  • 6.4.3 SERVICES
    • 6.4.3.1 Provision of customer-focused care to support market growth

7 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY PRICE RANGE

• 7.1 INTRODUCTION
• 7.2 LOW-RANGE HEMATOLOGY ANALYZERS
  • 7.2.1 LOW OPERATING EXPENSES TO BOOST DEMAND
• 7.3 HIGH-RANGE HEMATOLOGY ANALYZERS
  • 7.3.1 HIGH ACCURACY AND MULTI-PARAMETER APPROACH TO DRIVE MARKET
• 7.4 MID-RANGE HEMATOLOGY ANALYZERS
  • 7.4.1 INTEGRATION WITH QUALITY CONTROL SOFTWARE TO SUPPORT MARKET GROWTH

8 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 HEMORRHAGIC CONDITIONS
  • 8.2.1 ABILITY TO TRACK HEMOGLOBIN AND HEMATOCRIT VALUES TO DRIVE MARKET
• 8.3 INFECTIOUS DISEASES
  • 8.3.1 AVAILABILITY OF HIGH-RESOLUTION HEMATOLOGY SCREENING TO PROPEL MARKET
• 8.4 IMMUNE SYSTEM DISORDERS
  • 8.4.1 GROWING USE OF POC DIAGNOSTICS AND IMMUNOASSAYS TO PROPEL MARKET
• 8.5 BLOOD CANCER
  • 8.5.1 DETERMINATION OF HEMATOLOGICAL MALIGNANCIES TO FUEL UPTAKE
• 8.6 ANEMIA
  • 8.6.1 ABILITY TO IDENTIFY ISOCHROMATIC AND MICROCYTIC ANEMIA TO SUPPORT MARKET GROWTH
• 8.7 OTHER APPLICATIONS

9 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY USAGE TYPE

• 9.1 INTRODUCTION
• 9.2 STANDALONE ANALYZERS
  • 9.2.1 HIGH UPTAKE IN HOSPITALS AND REFERENCE LABORATORIES FOR CRITICAL CARE SETTINGS TO PROPEL MARKET
• 9.3 POINT-OF-CARE ANALYZERS
  • 9.3.1 LOW SAMPLE REQUIREMENTS AND REMOTE CARE AVAILABILITY TO BOOST DEMAND

10 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 COMMERCIAL SERVICE PROVIDERS
  • 10.2.1 GROWING OUTSOURCING OF R&D ACTIVITIES AND ABILITY TO PERFORM HIGH VOLUME OF TESTS TO PROPEL MARKET
• 10.3 HOSPITAL LABORATORIES
  • 10.3.1 PROVISION OF POC & FULLY AUTOMATED ANALYZERS TO DRIVE MARKET
• 10.4 GOVERNMENT REFERENCE LABORATORIES
  • 10.4.1 FREE SERVICES AND RAPID TURNAROUND TIME TO FUEL UPTAKE
• 10.5 RESEARCH & ACADEMIC INSTITUTES
  • 10.5.1 INCREASING NUMBER OF DRUG DISCOVERY & RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH

11 HEMATOLOGY ANALYZERS AND REAGENTS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 US
    • 11.2.1.1 Rising incidence of anemia and hemophilia to drive market
  • 11.2.2 CANADA
    • 11.2.2.1 Growth in organ transplantation procedures to boost demand
• 11.3 EUROPE
  • 11.3.1 GERMANY
    • 11.3.1.1 Rising prevalence of HIV to drive market
  • 11.3.2 FRANCE
    • 11.3.2.1 Stringent regulatory protocols in diagnostics to propel market
  • 11.3.3 UK
    • 11.3.3.1 Rising number of organ transplant procedures to support market growth
  • 11.3.4 ITALY
    • 11.3.4.1 Growing acceptance of hematology-based diagnostics to boost demand
  • 11.3.5 SPAIN
    • 11.3.5.1 Rising establishment of reference laboratories to drive market
  • 11.3.6 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 CHINA
    • 11.4.1.1 Large target patient population to drive market
  • 11.4.2 JAPAN
    • 11.4.2.1 Rising cases of influenza to support market growth
  • 11.4.3 INDIA
    • 11.4.3.1 Rising cases of dengue and malaria to boost demand
  • 11.4.4 AUSTRALIA
    • 11.4.4.1 Rising prevalence of celiac disease to drive market
  • 11.4.5 SOUTH KOREA
    • 11.4.5.1 High healthcare expenditure and introduction of medical coverage for blood transfusion to support market growth
  • 11.4.6 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 BRAZIL
    • 11.5.1.1 Investments by leading hematology analyzers & reagent manufacturers to drive market
  • 11.5.2 MEXICO
    • 11.5.2.1 Growing requirement for glycosylated hemoglobin analysis tests to fuel uptake
  • 11.5.3 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 GCC COUNTRIES
    • 11.6.1.1 Developments in healthcare infrastructure to drive market
  • 11.6.2 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYERS STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN HEMATOLOGY ANALYZERS AND REAGENTS MARKET
• 12.3 REVENUE ANALYSIS
• 12.4 MARKET SHARE ANALYSIS
  • 12.4.1 HEMATOLOGY PRODUCTS MARKET SHARE, BY KEY PLAYER, 2023
  • 12.4.2 HEMOSTASIS PRODUCTS MARKET SHARE, BY KEY PLAYER, 2023
  • 12.4.3 IMMUNOHEMATOLOGY PRODUCTS MARKET SHARE, BY KEY PLAYER, 2023
  • 12.4.4 RANKING OF KEY MARKET PLAYERS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPETITIVE FOOTPRINT: KEY PLAYERS, 2023
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Product & service footprint
    • 12.5.5.3 Application footprint
    • 12.5.5.4 End-user footprint
    • 12.5.5.5 Region footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
• 12.7 COMPANY VALUATION & FINANCIAL METRICS
  • 12.7.1 FINANCIAL METRICS
  • 12.7.2 COMPANY VALUATION
• 12.8 BRAND/PRODUCT COMPARISON
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 SYSMEX CORPORATION
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product/Service launches
      • 13.1.1.3.2 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 DANAHER CORPORATION
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products/Services offered
    • 13.1.2.3 MnM view
      • 13.1.2.3.1 Key strengths
      • 13.1.2.3.2 Strategic choices
      • 13.1.2.3.3 Weaknesses and competitive threats
  • 13.1.3 SIEMENS HEALTHINEERS
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products/Services offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Product/Service launches
      • 13.1.3.3.2 Deals
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Key strengths
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products/Services offered
    • 13.1.4.3 MnM view
      • 13.1.4.3.1 Key strengths
      • 13.1.4.3.2 Strategic choices
      • 13.1.4.3.3 Weaknesses and competitive threats
  • 13.1.5 ABBOTT LABORATORIES
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products/Services offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product approvals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses and competitive threats
  • 13.1.6 DIATRON
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products/Services offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Expansions
  • 13.1.7 DREW SCIENTIFIC
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products/Services offered
  • 13.1.8 BIO-RAD LABORATORIES, INC.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products/Services offered
    • 13.1.8.3 Recent developments
      • 13.1.8.3.1 Product/Service launches & enhancements
      • 13.1.8.3.2 Deals
  • 13.1.9 HORIBA, LTD.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products/Services offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Product/Service launches & approvals
  • 13.1.10 NIHON KOHDEN CORPORATION
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products/Services offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Product/Service launches
      • 13.1.10.3.2 Expansions
  • 13.1.11 EKF DIAGNOSTICS HOLDINGS PLC
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products/Services offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Product/Service enhancements
      • 13.1.11.3.2 Deals
  • 13.1.12 BOULE DIAGNOSTICS AB
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products/Services offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 PRODUCT/SERVICE LAUNCHES
      • 13.1.12.3.2 Deals
  • 13.1.13 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products/Services offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
• 13.2 OTHER PLAYERS
  • 13.2.1 BIOSYSTEMS: COMPANY OVERVIEW
  • 13.2.2 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • 13.2.3 DRUCKER DIAGNOSTICS: COMPANY OVERVIEW
  • 13.2.4 ELITECH GROUP SAS: COMPANY OVERVIEW
  • 13.2.5 ACCUREX: COMPANY OVERVIEW
  • 13.2.6 STRECK: COMPANY OVERVIEW
  • 13.2.7 NEOMEDICA: COMPANY OVERVIEW
  • 13.2.8 CPC DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
  • 13.2.9 MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW
  • 13.2.10 SHENZHEN DYMIND BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • 13.2.11 PZ CORMAY S.A.: COMPANY OVERVIEW
  • 13.2.12 PIXCELL MEDICAL: COMPANY OVERVIEW
  • 13.2.13 RAYTO LIFE AND ANALYTICAL SCIENCES CO. LTD.: COMPANY OVERVIEW
  • 13.2.14 ANALYTICON BIOTECHNOLOGIES GMBH: COMPANY OVERVIEW
  • 13.2.15 TULIP DIAGNOSTICS (P) LTD.: COMPANY OVERVIEW

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS